–
medRxiv This working paper aims to generate evidence on long-term anti-S IgG antibodies titers and their dynamics in individuals in Qatar who have completed a primary COVID-19 vaccination schedule. Working Paper
Read MoremedRxiv This working paper from Qatar provides evidence that having two SARS-CoV-2 infections, one with a pre-Omicron variant followed by one with an Omicron subvariant, elicits stronger protection against future Omicron-subvariant reinfection than having had only one infection with an Omicron subvariant. Working Paper
Read MoreNature Communications This article aims to investigate immune protection of infection with one sub-lineage against reinfection with the other sub-lineage in Qatar during a large BA.1 and BA.2 Omicron wave, from December 2021 to March 2022. Journal Article
Read MoreMayoClinic Proceedings – Innovations, Quality & Outcomes Journal This article aims to report whether cardiovascular diseases increase the risk for hospitalization and further complications in COVID-19 patients in Qatar Journal Article
Read MoreInternational Journal of Public Health This article aims to identify the limitations facing MACWs (Manual and Craft Workers) in Qatar towards practicing the COVID-19 preventive measures and thereby designing behavioral change strategies. Journal Article
Read MorePreventive Medicine Reports This article aims to determine the prevalence of tobacco use among COVID-19 patients in Qatar, and to examine the relationship between tobacco use and hospitalized COVID-19 (non-severe and severe), and quantify its risk factors. Journal Article
Read MoreFrontiers in Environmental Science This article examines how contingencies disrupt existing theoretical models and their implications for the post-COVID-19 era for online purchases. Journal Article
Read MorePLOS One This article presents the development of a COVID-19 risk score to guide targeted RT-PCR testing in Qatar in order to identify those at the highest risk of having the infection. Journal Article
Read MoreThe New England Journal of Medicine This article evaluates the effectiveness of vaccination with Pfizer–BioNTech or Moderna, natural immunity due to previous infection with variants other than omicron, and hybrid immunity (previous infection and vaccination) against symptomatic Omicron infection and against severe, critical, or fatal COVID-19. Journal Article
Read MoremedRxiv This working paper investigates the duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe SARS-CoV-2 reinfection, in Qatar, between February 28, 2020 and June 5, 2022. Working Paper
Read More